G1 Therapeutics Inc
NASDAQ:GTHX 4:00:00 PM EDT
| Market Cap (Intraday) | 376.17M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 54.85 |
| 10-Day MA | $7.10 |
| 50-Day MA | $5.20 |
| 200-Day MA | $3.90 |
G1 Therapeutics Inc Stock, NASDAQ:GTHX
700 Park Offices Drive, Suite 200, Research Triangle Park, North Carolina 27709
United States of America
Phone: +1.919.213.9835
Number of Employees: 100
Description
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.